Roche Holding AG Part. Cert.

Roche Holding is a healthcare company. Co. operates in two Divisions, Pharmaceuticals and Diagnostics. Co.'s pharmaceuticals division is comprised of two business segments Roche Pharmaceuticals and Chugai. Co.'s pharmaceuticals division provides therapies including Cotellic, in combination with Zelboraf for advanced melanoma, and Alecensa for a specific type of lung cancer. Co.'s diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. Co.'s diagnostics division provides in vitro diagnostic tests, used by healthcare providers to screen, diagnose and monitor therapies.
  • TickerROG
  • ISINCH0012032048
  • ExchangeSix Swiss Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountrySwitzerland
Eric Le Berrigaud

ROCHE: Putting the biosimilar impact more quickly behind it is not a bad thing | BUY | CHF390 vs. CHF395 (+26%)

ROCHE - BUY | CHF390 vs. CHF395 (+26%) Putting the biosimilar impact more quickly behind it is not a bad thing Biosimilars and China behind the soft Q3 performance The future is obviously new drugs-dependent Diagnostics should report booming Q4 performance The investment case is shifting now

Emira Sagaama ...
  • Jean-Baptiste Rouphael
  • Team Pharma

Roche Holding : Opinions ESG : exposé de notre méthode et application au secteur pharma

Nous présentons notre méthode d’analyse fondée sur une grille de 7 risques et 7 opportunités, couvrant les trois dimensions de l'ESG et les solutions aux grands enjeux de développement durable. Nous l’appliquerons progressivement à l'ensemble des valeurs suivies par le bureau d'analyse financière, et commençons ici par le secteur Pharma. Sur la base des risques et opportunités ESG matériels du secteur, notre best-in-class parmi les 6 valeurs européennes Pharma suivies par ODDO BH...

Emira Sagaama ...
  • Jean-Baptiste Rouphael
  • Team Pharma

Roche Holding : ESG opinions: overview of our method and application to pharma sector

We present our ESG analysis method based on a series of seven risks and seven opportunities covering the three ESG dimensions and the solutions to the major sustainable development challenges. It will gradually be applied to all the companies covered by the financial analyst department and we start with the pharma sector. Based on the most material ESG risks and opportunities in the sector, GSK is our best-in-class pick among the six European Pharma stocks covered by ODDO BHF Sec...

Ahmed Ben Salem ...
  • Louis Boujard, CFA

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10 Dear clients, We are very pleased to officially announce a partnership agreement between our group and BBVA in equity brokerage. In adding a new domestic market to its platform, ODDO BHF is looking t

With 40% upside, Eiffage is our Top Pick in the construction/concessions sector: whilst the contracting business should prove resilient thanks to alternative growth drivers (the “France Relance” stimulus plan in particular) and leverage on margins, cash flow generation (+35% estimated between 2019 and 2022) will be supported by higher dividends from motorway concessions. The group has 15 years to find an alternative to APRR and we have already identified numerous potential M&A possibi...

Ahmed Ben Salem ...
  • Louis Boujard, CFA

Total : Chers clients, Nous sommes très heureux de vous annoncer l’officialisation d’un accord de partenariat entre notre Groupe et BBVA dans les métiers de l’intermédiation actions. En ajoutant un nouveau marché domestique à sa plateforme, ODDO BHF souha

Avec 40% de potentiel, Eiffage est notre valeur préférée dans le secteur construction / concessions : alors que l’activité Travaux devrait s’avérer résiliente grâce aux relais de croissance (France Relance notamment) et au levier sur les marges, la génération de cash-flow (+35%e entre 2019 et 2022) va être soutenue par la hausse des dividendes des concessions autoroutières. Le groupe dispose de 15 ans pour trouver une alternative à APRR avec d’ores et déjà de nombreuses opportunités d...

Valérie GASTALDY

Analyse court terme - ROCHE HOLDING AG : Les cours progressent encore.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 243,70 CHF. La rupture du support à 206,50 CHF invaliderait cette tendance.

Valérie GASTALDY

Short term view - ROCHE HOLDING AG : Prices are still making progress

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at CHF 243.70. Breaking below the support at CHF 206.50 would invalidate the trend.

Valérie GASTALDY

Analyse court terme - ROCHE HOLDING AG : Les cours progressent encore.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 243,70 CHF. La rupture du support à 206,50 CHF invaliderait cette tendance.

Valérie GASTALDY

Short term view - ROCHE HOLDING AG : Prices are still making progress

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at CHF 243.70. Breaking below the support at CHF 206.50 would invalidate the trend.

Valérie GASTALDY

Medium term view - ROCHE HOLDING AG : The recent fall is getting more vigorous.

The trend is bullish. The recent fall is getting more vigorous. The next support is at CHF 203.60. A break below CHF 203.60 would challenge the trend.

Jean-Jacques Le Fur

Roche: Positive OS for Tecentriq in ES-SCLC (IMpower 133) after the disappointment in NSCLC

Brief Comment - Roche: (NEUTRAL, Fair Value CHF266 (+14%)) Positive OS for Tecentriq in ES-SCLC (IMpower 133) after the disappointment in NSCLC

Eric Le Berrigaud

ROCHE: Putting the biosimilar impact more quickly behind it is not a bad thing | BUY | CHF390 vs. CHF395 (+26%)

ROCHE - BUY | CHF390 vs. CHF395 (+26%) Putting the biosimilar impact more quickly behind it is not a bad thing Biosimilars and China behind the soft Q3 performance The future is obviously new drugs-dependent Diagnostics should report booming Q4 performance The investment case is shifting now

Emira Sagaama ...
  • Jean-Baptiste Rouphael
  • Team Pharma

Roche Holding : Opinions ESG : exposé de notre méthode et application au secteur pharma

Nous présentons notre méthode d’analyse fondée sur une grille de 7 risques et 7 opportunités, couvrant les trois dimensions de l'ESG et les solutions aux grands enjeux de développement durable. Nous l’appliquerons progressivement à l'ensemble des valeurs suivies par le bureau d'analyse financière, et commençons ici par le secteur Pharma. Sur la base des risques et opportunités ESG matériels du secteur, notre best-in-class parmi les 6 valeurs européennes Pharma suivies par ODDO BH...

Emira Sagaama ...
  • Jean-Baptiste Rouphael
  • Team Pharma

Roche Holding : ESG opinions: overview of our method and application to pharma sector

We present our ESG analysis method based on a series of seven risks and seven opportunities covering the three ESG dimensions and the solutions to the major sustainable development challenges. It will gradually be applied to all the companies covered by the financial analyst department and we start with the pharma sector. Based on the most material ESG risks and opportunities in the sector, GSK is our best-in-class pick among the six European Pharma stocks covered by ODDO BHF Sec...

Martial Descoutures ...
  • Sebastien Malafosse

Roche Holding : Q3 still weak but full-year guidance maintained

>Q3 2020 sales up 1% at constant currency - Roche reported disappointing Q3 sales, 4% below the consensus expectations (FactSet), up 1% at constant currency (cc) but marked as expected by a highly negative currency effect (-7%). In detail, the historic franchise (Avastin, MabThera and Herceptin) remain penalised by competition from biosimilars (declines of 30-38% cc) and disappointed the consensus. Even Actemra, which continues to benefit from COVID-19 sales over the ...

Martial Descoutures ...
  • Sebastien Malafosse

Roche Holding : Un T3 encore faible mais une guidance annuelle maintenue

>CA T3 en croissance de 1% à changes constants - Le CA T3 de Roche est décevant, 4% sous les attentes du consensus (FactSet) en croissance de 1% à changes constant mais marqué comme attendu par un fort effet changes négatif (-7%). Dans le détail, la franchise historique (Avastin, MabThera et Herceptin) continue de souffrir de la concurrence biosimilaire (baisses de 30 à 38% à changes constants) et déçoit le consensus. Même Actemra qui continue de profiter de ventes CO...

Roche Holding – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Roche - March, 05th 2019

ITEMS 2.1, 2.2, 7 and 8 - Binding votes on the remuneration of the board of directors  and the executive management. Ethos has the following concerns over the amounts requested:  The annual bonuses that will effectively be paid out to the chairman and the CEO are significantly higher than the amounts requested at the general meeting. The remuneration of the non-executive chairman is significantly higher than that of the peer group and includes an annual bonus. For the executive management, the remuneration is significantly higher than that of the peer group and the remuneration structure is n...

Roche Holding AG - June 2020 (LTM): Peer Snapshot

Peer Snapshot:  Roche Holding AG - June 2020 (LTM) 28 August 2020 (in US millions) FYE Dec-18 FYE Dec-19 LTM Jun-20 FYE Dec-18 FYE Dec-19 LTM Mar-20 FYE Dec-18 FYE Dec-19 LTM Jun-20

Roche Holding AG: Update following Q1 2020 sales

Our credit view of Roche, reflecting the strong growth of its recently launched products that will offset biosimilar erosion, allowing for continued strong cash flow generation.

Roche Holding AG - December 2019 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Roche Holding AG: Update following outlook change to positive

Our credit view of Roche, reflecting the strong growth of its recently launched products that will offset biosimilar erosion, allowing for continued strong cash flow generation.

Roche Holding AG: Update to credit analysis

Our credit view of Roche, which will continue to maintain strong credit metrics despite sale pressures from biosimilar competition in 2020.

Ahmed Ben Salem ...
  • Louis Boujard, CFA

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10 Dear clients, We are very pleased to officially announce a partnership agreement between our group and BBVA in equity brokerage. In adding a new domestic market to its platform, ODDO BHF is looking t

With 40% upside, Eiffage is our Top Pick in the construction/concessions sector: whilst the contracting business should prove resilient thanks to alternative growth drivers (the “France Relance” stimulus plan in particular) and leverage on margins, cash flow generation (+35% estimated between 2019 and 2022) will be supported by higher dividends from motorway concessions. The group has 15 years to find an alternative to APRR and we have already identified numerous potential M&A possibi...

Ahmed Ben Salem ...
  • Louis Boujard, CFA

Total : Chers clients, Nous sommes très heureux de vous annoncer l’officialisation d’un accord de partenariat entre notre Groupe et BBVA dans les métiers de l’intermédiation actions. En ajoutant un nouveau marché domestique à sa plateforme, ODDO BHF souha

Avec 40% de potentiel, Eiffage est notre valeur préférée dans le secteur construction / concessions : alors que l’activité Travaux devrait s’avérer résiliente grâce aux relais de croissance (France Relance notamment) et au levier sur les marges, la génération de cash-flow (+35%e entre 2019 et 2022) va être soutenue par la hausse des dividendes des concessions autoroutières. Le groupe dispose de 15 ans pour trouver une alternative à APRR avec d’ores et déjà de nombreuses opportunités d...

Emmanuel Matot

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/09/2020

The group has raised its COVID scenario twice, a clear indication that sales and margins are holding up well against the current health crisis. The second half of the year appears to point to stable sales l-f-l and we expect the group to return to more normative growth in 2021. The balance sheet is very healthy and acquisitions can be made. We are raising our rating to Buy from Neutral and lifting our target price to € 177 from € 160. - ...

Emmanuel Matot

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 09/10/2020

Le titre Scor a nettement sous-performé le secteur et ses grands concurrents depuis le début de l’année, compte tenu notamment de l’impact COVID sur la mortalité US et de l’abandon du dividende 2019. Or, le coût COVID reste maîtrisé et les perspectives de résultats et de dividendes favorables sur 2021/2022. Nous réitérons notre recommandation Achat avec un objectif de cours relevé à 33 € (vs 31 €). - ...

Anthony Dick ...
  • Emna Ben Bdira
  • Martial Descoutures
  • Michael Foundoukidis
  • Nour Robbana
  • Oussema Denguir
  • Sebastien Malafosse

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 09/15/2020

...

For ROCHE HOLDING AG, the environment deterioration entails a downgrade to Neutral

ROCHE HOLDING AG (CH), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener just confirmed the fundamental rating of 4 stars out of 4, as well as the stock market behaviour of the title as moderately risky. However, environmental deterioration penalises the general evaluation, which is downgraded to Neutral. As of the analysis date December 31, 2019, the closing price was CHF 314.00 and its expected value was estimated at CHF 303.28.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch